Skip to main content
. Author manuscript; available in PMC: 2012 Aug 28.
Published in final edited form as: Leukemia. 2008 May 29;22(8):1595–1603. doi: 10.1038/leu.2008.129

Figure 2. IL-22 modulated cell proliferation in ALK+ALCL cell lines.

Figure 2

Treatment of SU-DHL-1 with recombinant IL-22 induced a significant increase in the number if viable cells, whereas treatment with IL-22BP or IL-22 neutralizing antibody resulted in a significant decrease in viable cells (trypan blue exclusion assay). No significant change was seen in Jurkat cells and benign peripheral blood lymphocytes.